In vitro antifungal activity of domestic amphotericin B and other common antifungal agents against pathogenic fungi isolated from invasive fungal disease

Abstract

Abstract:

Objective To investigate the in vitro antifungal activity of domestic amphotericin B and other common antifungal agents against the clinical isolates associated with invasive fungal disease. Methods Minimal inhibitory concentration (MIC) or minimum effect concentration (MEC) of domestic amphotericin B and other common antifungal agents against 108 strains associated with invasive fungal disease were tested by using CLSI (Clinical and Laboratory Standards Institute) broth microdilution method M27-A3 and M38-A2. Results The MICs of amphotericin B against almost all strains tested were less than or equal to 2 mg/L, except Aspergillus terreus, Scedosporium prolificans and S. apiospermum (MIC range of 2-4 mg/L, >16 mg/L, 1-8 mg/L, respectively). The MICs of amphotericin B against azole-resistant Candida and Aspergillus were less than or equal to 2 mg/L. The MICs of fluconazole against all the filamentous fungi tested were greater than 64 mg/L. The MICs of itraconazole against Fusarium solani, S. prolificans and Mucor circinelloides were 8 mg/L, >16 mg/L, >16 mg/L, respectively. The MICs of voriconazole against F. solani, S. prolificans and all Mucor tested were greater than 16 mg/L. The MICs of posaconazole against Fusarium solani, S. prolificans and Mucor circinelloides were all greater than 16 mg/L. The MICs/MECs of caspofungin and micafungin against Cryptococcus, Trichosporon, Mucor, F. solani and Scedosporium were all greater than 16 mg/L. The MECs of caspofungin and micafungin against S. prolificans were 8 and 4 mg/L, respectively. Conclusion Compared with other common antifungal agents, amphotericin B is active against the clinical isolates associated with invasive fungal disease, except A. terreus and Scedosporium.

Key words: antifungal agent, amphotericin B, in vitro susceptibility tests, pathogenic fungi

CLC Number:

R978.5

ZHOU Ya-bin, WANG Qian, ANG Hao, WAN Zhe, LI Ruo-yu, Liu Wei. In vitro antifungal activity of domestic amphotericin B and other common antifungal agents against pathogenic fungi isolated from invasive fungal disease[J]. Chinese Journal of Mycology, 2018, 13(5): 277-282.

References

[1] Enoch DA, Yang H, Aliyu SH, et al. The Changing Epidemiology of Invasive Fungal Infections[J]. Methods Mol Biol, 2017, 1508(Suppl 1):17-65.
[2] Barnes PD, Marr KA. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients[J]. Br J Haematol, 2007, 139(4):519-531.
[3] Hamill RJ. Amphotericin B formulations:a comparative review of efficacy and toxicity[J]. Drugs, 2013, 73(9):919-934.
[4] Clinical and Laboratory Standards Institute.Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved Standard-Third Edition.CLSI document M27-A3[S].Wayne,PA:Clinical and Laboratory Standards Institute, 2008.
[5] Clinical and Laboratory Standards Institute.Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; Approved Standard-Second Edition.CLSI document M38-A2[S].Wayne,PA:Clinical and Laboratory Standards Institute, 2008.
[6] Cao C, Liu W, Li R, et al. In vitro interactions of micafungin with amphotericin B, itraconazole or fluconazole against the pathogenic phase of Penicillium marneffei[J]. J Antimicrob Chemother, 2009, 63(2):340-342.
[7] 李强国, 李昕, 曹存巍. 两种钙调磷酸酶抑制剂联合常用抗真菌药物对马尔尼菲青霉酵母相体外药敏的研究[J]. 广西医科大学学报, 2015, 32(2):169-172.
[8] Clinical and Laboratory Standards Institute.Reference method for broth dilution antifungal susceptibility testing of yeasts; Fourth Information Supplement. CLSI document M27-S4[S].Wayne,PA:Clinical and Laboratory Standards Institute, 2012.
[9] Pastor FJ, Guarro J. Treatment of Aspergillus terreus infections:a clinical problem not yet resolved[J]. Int J Antimicrob Agents, 2014, 44(4):281-289.
[10] Fera MT, La CE, De SA. New triazoles and echinocandins:mode of action, in vitro activity and mechanisms of resistance[J]. Expert Rev Anti Infect Ther, 2009, 7(8):981.
[11] Montoya AM, Sánchez González A, Palma-Nicolás JP, et al. Genotyping, extracellular compounds, and antifungal susceptibility testing of Trichosporon asahii isolated from Mexican patients[J]. Med Mycol, 2015, 53(5):505-511.
[12] Tomazin R, Matos T, Meis JF, et al. Molecular characterization and antifungal susceptibility testing of sequentially obtained clinical Cryptococcus deneoformans and Cryptococcus neoformans isolates from Ljubljana, Slovenia[J]. Mycopathologia, 2018, 183(6):371-380.
[13] Gupta C, Jongman M, Das S, et al. Genotyping and in vitro antifungal susceptibility testing of Fusarium isolates from onychomycosis in India[J]. Mycopathologia, 2016, 181(7-8):497-504.
[14] Homa M, Galgóczy L, Tóth E, et al. In vitro antifungal activity of antipsychotic drugs and their combinations with conventional antifungals against Scedosporium and Pseudallescheria isolates[J]. Med Mycol, 2015, 53(8):890-895.
[15] 王澎, 徐英春, 窦洪涛,等. 尖端赛多孢和多育赛多孢所致的深部真菌感染2例并文献复习[J]. 中国真菌学杂志, 2007, 2(4):210-213.
[16] Drogari-Apiranthitou M, Mantopoulou FD, Skiada A, et al. In vitro antifungal susceptibility of filamentous fungi causing rare infections:synergy testing of amphotericin B, posaconazole and anidulafungin in pairs[J]. J Antimicrob Chemother, 2012, 67(8):1937-1940.
[17] Vitale RG, de Hoog GS, Schwarz P, et al. Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales[J]. J Clin Microbiol, 2012, 50(1):66-75.
[18] Chowdhary A, Kathuria S, Singh PK, et al. Molecular characterization and in vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India[J]. Mycoses, 2015, 57(s3):97-107.